Filter
607
Text search:
pharmaceutical
regulatory
authority
Featured
Recommendations
52
New Publications
198
Language
Document type
No document type
335
Studies & Reports
104
Guidelines
88
Manuals
34
Strategic & Response Plan
26
Fact sheets
8
Situation Updates
5
Training Material
4
Resource Platforms
2
Brochures
1
Countries / Regions
Kenya
36
Ethiopia
31
India
25
Uganda
24
South Africa
20
Ghana
17
Tanzania
17
Liberia
16
Rwanda
16
Nigeria
15
Zambia
15
Malawi
13
Nepal
11
Sierra Leone
10
Zimbabwe
10
Western and Central Europe
10
Bangladesh
9
Namibia
8
Ukraine
8
Myanmar / Burma
8
Lesotho
7
Global
7
Eastern Europe
6
Philippines
5
Indonesia
5
Eswatini/ Swaziland
5
Botswana
5
Syria
4
Cambodia
4
Benin
3
Albania
3
Guinea
2
Senegal
2
Congo, Democratic Republic of
2
Cameroon
2
Haiti
2
Pakistan
2
Jordan
2
Thailand
2
West and Central Africa
2
Middle East and North Africa
2
South–East Asia Region
2
Eastern Europe and Central Asia
2
Asia
2
Africa
2
Laos
2
USA
1
Somalia
1
Afghanistan
1
Germany
1
Chad
1
Mozambique
1
Papua New Guinea
1
Sudan
1
North Macedonia
1
East and Southern Africa
1
Western Pacific Region
1
Latin America and the Carribbean
1
Fiji
1
Timor Leste/ East Timor
1
Moldova
1
Australia
1
Vietnam
1
Gabon
1
Denmark
1
Maldives
1
Authors & Publishers
Publication Years
Category
Countries
325
Clinical Guidelines
33
Pharmacy & Technologies
19
Key Resources
17
Public Health
9
Women & Child Health
8
Capacity Building
3
Toolboxes
Pharmacy
88
AMR
81
COVID-19
30
TB
23
Rapid Response
22
HIV
19
Mental Health
17
Global Health Education
9
Ebola
6
Conflict
6
Planetary Health
6
Health Financing Toolbox
5
NCDs
4
Specific Hazards
3
Caregiver
3
NTDs
3
Polio
2
Refugee
2
Natural Hazards
1
Zika
1
IN THE AMOUNT OF SDR 21.8 MILLION (US$30 MILLION EQUIVALENT) WITH AN ADDITIONAL GRANT FROM THE GLOBAL FINANCING FACILITY (GFF) IN THE AMOUNT OF US$ 10 MILLION TO THE DEMOCRATIC REPUBLIC OF CONGO FOR A HUMAN DEVELOPMENT SYSTEMS STRENGTHENING PROJECT
The Third Rwandan Health Sector Strategic Plan (HSSP III) provides strategic guidance to the health sector for six years, between July 2012 and June 2018. HSSP III has been inspired and guided by the VISION 2020, which will make Rwanda a lower-middle-income country by 2020; the Rwandan Health Policy
...
Accessed November, 2017
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these
...
Reporting system for the general public - This document aims to provide practical guidelines on how to set up national systems for consumers to report adverse reactions to medicines. The purpose is to help countries set up a well-organized and effective consumer reporting system within their pharmac
...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s
...
The prevalence, availability, and use of antimalarial medicines (AMLs) were studied in six Cambodian provinces along the Thai-Cambodian border. The study was divided into two parts: the first looked at the quality of AMLs available in Pursat, Pailin, Battambang, Bantey Meanchey, Oddar Meanchey, and
...
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi
...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council’s current thinking on the safety, quality and efficacy of medicines.
This CPD Policy relates to all health professionals in the four Health Professional Councils in Rwanda namely; RMDC, NCNM, RAHPC, and RPC. The policy requires all health professionals to participate in the CPD Programs. The purpose of this CPD Policy is to support the professionals in the respective
...
